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CLINICAL PRACTICE
Treattnent of tuberculosis in patients with pre-existing
liver disease or following hepatotoxic drug reactions
s. c. ROBSON, P. PILLANS, P. A. WILLCOX
T:earment schedules for the majority of patientswith pulmonary tuberculosis are now standardand highly effective.' There are, however, impor-
tant considerations which we feel require clarification
with regard to the initiation of treatment in patients with
evidence of acute or chronic liver disease. The manage-
ment of tuberculosis following drug-induced severe
hepatitis remains' a vexed problem because of increasing
mycobacterial drug resistance and the poor response of
many patients to suboptimal second-line therapy. We
feel that the guidelines from our institution published in
19862 should be revised in the light of these difficulties.
Abnormalities of drug metabolism that occur in liver
disease result from ponal systemic shunting and hepato-
cyte dysfunction. These result in significant abnormali-
ties in the.pharmacokinetics and pharmacodynamics of
several commonly used antituberculosis drugs.'
The overall incidence of drug-induced hepatitis after
'rifampicin, isoniazid or pyrazinamide therapy in all
patients is considered acceptably low (less than 0,1 %)"
Patients with liver disease are subject, however, to a
greater incidence of idiosyncratic and direct hepatotoxi-
city.' This is considered significant by the British
National Formulary, which advises that isoniazid and
pyrazinamide be avoided in patients with liver disease
wherever possible.· Rifampicin, the most potent of the
bactericidal antituberculosis agents, is a vital component
of all short-course chemotherapy regimens. Precise
dosage is imponant because there is a narrow margin
between the minimum effective dose and toxic levels.'
Hepatitis is associated with higher blood levels and
longer periods of exposure.8 In liver disease, rifampicin
induction of P450 enzyme systems may be less efficient
and dose reduction should be considered" Rifampicin is
excreted in high concentrations in bile. In cholestasis
with jaundice, therefore, further dose reductions may be
required.9,1O
Patients with decompensated liver disease and active
pulmonary tuberculosis should receive antituberculosis
therapy in hospital under close supervision. These
patients should not receive pyrazinamide at the onset of
therapy, but may be started on rifampicin at 5
mg/kg/day (standard dose 9 mg/kg/day), isoniazid 5
mg/kg/day (up to 300 mg if well tolerated), and etham-
butol 25 mg/kg/day. Streptomycin may be used if the
patient has well-preserved renal function, adequate
muscle bulk and no haemostatic problems. Quinolones
should not be considered as first-line drugs."
Malnourished patients with extensive pulmonary
tuberculosis with a background of alcohol abuse often
have unrecognised liver dysfunction. Ideally, these
patients should be stabilised in hospital and receive ade-'
quate nutritional support before the introduction of
pyrazinamide. '2 Patients with a history of excessive alco-
hol consumption, chronic consumption of enzyme-
inducing :drugs such as anticonvulsants, chronic viral
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hepatitis or clinical pointers to possible liver disease
should be considered an 'at risk' group. Pre-therapy
liver enzymes, albumin and prothrombin INR levels
should be determined."" Regular clinical evaluation is
imperative and repeat liver enzyme level assessments
should be performed at 2, 4 and 6 months.
Antituberculosis drug-induced liver injury usually
occurs on an idiosyncratic basis. 14 It is usually impossi-
ble confidently to predict the guilty agent where multi-
ple drug regimens have been employed. There are few
controlled data to direct rational and safe drug substitu-
tion and rechallenge.",,14 Minor elevations in transami-
nase levels due to isoniazid and unassociated with clini-
cal disease occur in up to 20% of patients treated and
may be associated with patchy necrosis of liver cells."
Severe reactions to isoniazid usually occur with concur-
rent administration of anrituberculosis drugs which
induce microsomal P450 enzyme systems, such as
rifampicin or pyrazinamide."I2,,· However, in a survey of
13 838 patienrs treated only with 300 mg isoniazid
daily, 114 cases of jaundice and 13 deaths occurred."
Liver disease was noticeable between 2 and 11 months
after commencing therapy. Late onset of jaundice with
serum bilirubin levels greater than 340 f..lITIol/l were asso-
ciated \vith a poor prognosis. High monaliry rates were
noted in blacks, women and patients over 30 years of
age." There are no consistent data that increased risks
of isoniazid drug reactions occur in patients with rapid
acetylator status. ",'8 Whether or not isoniazid causes
drug-induced chronic active hepatitis remains contro-
versial.'9
Rifampicin is the cause of drug-induced hepatitis in
1 - 4% of patients treated solely with this drug. Patients
who develop symptoms within 3 weeks of starting
therapy are panicularly likely to show evidence of severe
disease.'··20 Although continuation or reintroduction of
rifampicin therapy may be compatible with a full recov-
ery from hepatitis and liver injury/a this course of action
may also be fatal.
Pyrazinamide appears to be more frequently impli-
cated in hepatotoxic reactions than the other antituber-
culosis drugs and should be used with caution.21 The
underlying mechanisms are uncertain but hepatitis is
often severe enough to cause death if the drug is not dis-
continued. 21 •22 The onset of hepatitis may either be rapid
or more commonly, delayed for up to 5 - 6 months from
the start of therapy. Ethionamide has also been linked
with late-onset hepatitis, which may even be fata!.23
Ethambutol and streptomycin are infrequently, if ever,
hepatotoxic. '
At Brooklyn Chest Hospital in Cape Town, there are
on average 4 cases of significant drug-induced hepatitis
per 1 000 cases treated for tuberculosis.21 About half of
severe liver reactions secondary to drug therapy at
Groote Schuur Hospital are thought to be caused by
anriruberculosis therapy." Approximately 40% of
patients with hepatitis, jaundice and encephalopathy
secondary to antituberculosis therapy die.2'.2.
When a patient develops jaundice while taking anti-
ruberculosis drugs, these should be discontinued. A
decision then has to be made whether to continue treat-
menr with non-hepatotoxic drugs or whether to wait
until clinical and biochemical recovery has taken place
and rechallenge.'-" In all instances careful risk-benefit
analyses are mandatory.
-
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It is imponant to recognise that patients who develop
jaundice on antituberculosis therapy do not always have
drug-induced liver disease. Other causes of jaundice
such as extrahepatic biliary obstruction, viral hepatitis,
alcohol abuse, and hean failure must be considered. A
liver biopsy may be necessary to confirm or exclude
these other diagnoses. It is self-evident that the diagnosis
of tuberculosis should be re-examined in those patients
where there is no initial bacteriological proof of the diag-
nosis.
For practical purposes the issues of antituberculosis
drug substitution and challenge follO\ving drug-induced
liver injury can be classified into three major groups.
Firstly, there are patients who develop minimal jaun-
dice or develop abnormal transaminase levels (in excess
of fivefold normal range). Although these patients may
not be acutely ill from tuberculosis, reconsideration
should be given to admission and monitoring in hospital
at the time liver injury is recognised. Antituberculosis
therapy should be discontinued until the clinical condi-
tion improves, bilirubin levels return to the normal
range, and the serum transaminase values are on a
downward trend.
We recommend that selected patients who require
effective antituberculosis therapy then be rechallenged
\',~th isoniazid in standard dosage (day 1). liver function
tests should be checked 48 - 72 hours after drug expo-
sure. If this initial test dose is well tolerated the drug
may be continued for a further 5 days Mth repeat liver
function tests on day 8. If there are no further untoward
effects, after a further break of 3 days, rifampicin may be
introduced at standard dosage (day 12). I O drugs are
administered for the next 2 days after which liver func-
tion tests are re-checked (day 15). Rifampicin is then
administered daily foi- a further 5 days and liver function
tests again checked at the end of this treatment (day
21). After this isoniazid is reintroduced with rifampicin
and again liver function tests should be monitored.
These patients also receive ethambutol in standard
dosages, which may be conveniently initiated at the
introduction of isoniazid therapy. We do not recom-
mend the reintroduction of pyrazinamide except under
highly unusual circumstances. Patients with pulmonary
tuberculosis should receive triple drug therapy for a total
of 9 months unless they have already received at least 2
months' therapy with pyrazinamide, rifampicin and iso-
niazid.
Secondly, there are patients who are severely ill \',~th
extensive pulmonary tuberculosis, miliary tuberculosis
or tuberculous meningitis. In the event of suspected
drug-induced hepatitis the offending drug regimen
should be discontinued. These patients should bowever
then receive 'interim therapy' while awaiting resolution
of liver injury. An arninoglycoside (either streptomycin,
or intravenous amikacin if the patient has a severe coag-
ulopathy or has minimal muscle bulk), ethambutol and
a quinolone (ofloxacin 400 mg tMce daily) are our cur-
rently recommended drugs under these circumstances.
Renal function should be monitored and dose adjust-
ments made to all 3 drugs according to the serum creati-
nine levels. After normalisation of jaundice and liver
injury, patients should be rechallenged as before with
isoniazid and rifampicin and treated Mth 3- or 4-drug
therapy for at least 9 months.
Finally, there are patients who develop severe acute
or fulminant liver failure following antituberculosis
therapy. If warranted these patients should receive in-
terim antituberculosis therapy as described above. All
patients should receive adequate supportive therapy for
acute liver failure to facilitate hepatic regeneration and
recovery which will occur in approximately 60% of
cases. After normalisation of liver tests in those patients
who survive, a careful risk-benefit analysis should be
undenaken. If deemed necessary patients may be cau-
tiously rechallenged with isoniazid and rifampicin
according to the schedule as described above. If this
approach is nor considered justified then ethambutol,
streptomycin, ethionamide and ofloxacin should be
administered. Treatment should continue for 18
months. If the pulmonary tuberculosis does nor appear
to respond to this regimen, then we would recommend
either that these patients be challenged Mth isoniazid
and rifampicin as described above, or receive an amino-
glycoside or additional second-line drugs, viz. teri-
zidone, kanamycin, amoxycillin Mth c1avulanic acid.
If'patients develop jaundice or are noted to have sig-
nificant increases in transaminase values after admini-
stration of isoniazid or rifampicin, the offending drug
must be discontinued immediately. Such information
from a drug challenge may therefore help identify the
agent responsible. These patients may then be starred
on 'interim therapy' as described above and receive
additional second-line drugs. This therapy has a lower
rate of success and needs to be administered for up to
18 months. The possibility of drug-resistant tuberculosis
should bc cxcluded in non-responsive cases by appropri-
ate sputum culture techniques. Surgical options may
need to be explored at a later point.
There are no readily available laboratory tests which
may usefully predict the agent responsible for drug-
induced hepatitis in the setting of multiple drug admini-
stration.3.,,14
Rechallenge after drug-induced hepatitis is danger-
ous. Wherever possible this should only be done in hos-
pital after consultation Mth and under close supervision
of clinicians experienced in the management of acute
liver failure. 2",:!' Even then fatalities may occur. After the
reintroduction of antituberculosis therapy, all patients
must be carefully monitored during the remainder of
their course of therapy.
Severe drug-induced hepatitis during the treatment
of tuberculosis is an unusual complication. However,
because of the large numbers of patients treated for
tuberculosis/,,27 this remains an important medical
problem, The prognosis of established severe drug-
induced hepatitis is dismal, particulary if patients con-
tinue on the implicated drugs. 4,21 The predisposition of
patients Mth alcohol abuse and established liver disease
to tuberculosis2' is further complicated by an increased
likelihood of drug-induced hepatitis. 3.5 Antituberculosis
chemotherapy according to standard schedules may le.ad
to high rates of iatrogenic liver damage in patients who
have diminished hepatic reserves."I'
The above guidelines are intended to be practical
and applicable to general clinical practice. In all cases,
however, flexibility and individualised clinical judge-
ment are most imporrant.
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'Map and zap' - electrode catheter techniques for
treattnent of supraventricular tachycardias
R. N. SCOTT MILLAR, D. A. MILNE, I. w. P. OBEL
C ardiac electrophysiologists around the worldhave become increasingly interested in the use ofelectrode catheters to ablate critical areas
involved in the genesis and transmission of supra-
ventricular tacbycardias (svrs). 1bis interest has been
stimulated by the demonstration that accessory atrio-
ventricular (AV) connections in patients with Wolff-
Parkinson-White (WPW) syndrome can be selectively
damaged by radiofrequency energy (RP) delivered via
catheters insened percutaneously without general anaes-
thesia. The technique and results of its use were the
main topics of interest at the 9th World Symposium on
Cardiac Pacing and Electrophysiology held in
Washington, DC, in June 1991. Effective cure of WPW
syndrome entailing freedom from tachycardias without
drug treatment has been reponed in more than 90% of
patients undergoing this procedure. I Not surprisingly,
this has generated a great deal of excitement as previ-
ously these patients required either lifelong treatment
with potentially toxic anti-arrhythmic drugs or open-
hean surgery to ablate the accessory AV pathways
responsible for the tachycardias.2 The SVTs which are
amenable to treatment with RF current include atrial
fibrillation and flutter with uncontrollable ventricular
response (AV node ablation), ths: WPW syndrome
(accessory pathway ablation) and the extremely com-
mon form of SVT, AV nodal re-entrant tachycardia (AV
node modification).
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Practical techniques for the control of SVTs by
means of catheter ablation were first described in
1982Y High-energy DC shocks from a defibrillator
were transmitted via an electrode adjacent to the His
bundle. The aim was to induce complete hean block
to allow control of the ventricular rate in patients with
atrial flutter or fibrillation, otherwise uncontrollable by
drugs. Successful induction of complete hean block
required the implantation of a permanent pacemaker.
General anaesthesia was required because of the pain
and muscle spasm induced by the DC shock. The high
energies (200 - 300 J) resulted in arcing at the catheter
tip and vaporisation of blood that produced transient
pressures up to 20 atmospheres.' The resulting baro-
trauma may have been responsible for ventricular dys-
function and the production of arrhythmogenic foci.
Late sudden death has occurred in a small number of
patients.6 In addition, AV conduction recurred hours to
months later in a sizeable number of patients, presum-
ably because the AV node or proximal bundle of His
had been stunned rather than destroyed.
Alternative energy sources were therefore developed.
Modification of the output of the defibrillator allowed
the use of much lower energies (20 - 50 J), avoiding the
barotrauma while preserving the high-voltage heating
effect of the shock.' 1bis method is still in use, whereas
high-energy DC shock has largely been abandoned. In
1987, the use of RP energy from standard surgical
cautery machines was reponed. 8,- It was shown that
small, discrete lesions could be produced, providing the
catheter was in contact with the endocardium and suc-
cessful ablation of the AV node could be achieved. 'o
Because RF energy does not affect nerves or muscles,
general anaesthesia is not necessary. The homogeneous
lesions produced seem less likely to result in new
arrhythmias. The safety of the technique was somewhat
offset by a lower efficacy, probably because of the build-
-
